Group items matching

in title, tags, annotations or url

কাইফোসিসের চিকিত্সার বিকল্পগুলি রোগীর অবস্থা, বয়স এবং সামগ্রিক স্বাস্থ্যের ধরন এবং তীব্রতা সহ বিভিন্ন কারণের উপর নির্ভর করে।

Exertional angina is a critical cardiovascular condition characterized by having a form of chest pain or discomfort triggered when you engage in physical exertion or emotional stress. Let me explore exertional angina in depth, including its symptoms, causes, diagnosis, classification, and available treatments.

How does your physician perform costochondritis treatment? First things first, Costochondritis is the inflammation of your rib cage i.e. bone/cartilage connecting the ribs to the sternum (breastbone), and can be a source of significant discomfort as I have clearly defined in the costochondritis symptoms section. Costochondritis is one of the most common causes of breast pain in ladies. Here In this guide, I will delve deeper into the various treatment options and approaches to manage costochondritis, considering a wide range of methods that reflect the diverse ways you can seek relief and healing.

How do you diagnose angina at home? angina, a common symptom of coronary artery disease, occurs when the heart muscle doesn't receive enough blood and oxygen, resulting in chest pain or discomfort as reported by Johns Hopkins Medicine. While angina diagnosis and management typically require medical expertise, there are ways to monitor your symptoms and assess your risk for angina at home. In this piece, I will provide a comprehensive guide on angina testing at home.

Consumer healthcare group Haleon on Thursday announced that it has entered into a binding agreement for the sale of the ChapStick brand to Suave Brands Company, a company owned by American private equity firm Yellow Wood Partners. The British consumer healthcare company has agreed to sell its lip balm brand to Suave for about $430 million in cash and a minority interest in the buyer, valued at around $80 million. Haleon, which was spun off from the GSK Group in July 2022, said that cash proceeds from the sale would be used to pay down debt. ChapStick generated £112 million ($142.5 million) in revenue in 2023, said Haleon, adding that the sale is likely to close in the second quarter of 2024. Brian McNamara, Chief Executive Officer, Haleon, said: "Today's announcement is consistent with Haleon being proactive in managing our portfolio, and being rigorous and disciplined where there are opportunities for divestment. "While ChapStick is a great brand, much loved by consumers around the world, it is not a core focus for Haleon.